Latest News and Press Releases

TEL AVIV, Israel, March 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate and business...

TEL AVIV, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead...

TEL AVIV, Israel, Feb. 01, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D.,  will provide a corporate overview and...

TEL AVIV, Israel, Dec. 1, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the grant of US Patent No. 9,200,056, entitled "A Fas-Chimera Adenovirus Vector" by the United State...

TEL AVIV, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...

Initiated GLOBE™ pivotal Phase 3 trial of VB-111 in recurrent glioblastoma (rGBM) Reported positive, final Phase 2 data of VBL-111 in rGBM at the European Cancer Conference (ECC)...

TEL AVIV, Israel, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ:VBLT), today announced the closing of its underwritten offering of 2,500,000...

TEL AVIV, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...

TEL AVIV, Israel, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ:VBLT), today announced the pricing of an underwritten offering of 2,500,000...